Evidence map›Paper›PMID 38176833›Full record

ArticleMayo Clinic proceedings2024

Impact of Thyroid Status on Incident Kidney Dysfunction and Chronic Kidney Disease Progression in a Nationally Representative Cohort.

Amy S You, Kamyar Kalantar-Zadeh, Gregory A Brent, Yoko Narasaki, Andrea Daza, John J Sim, Csaba P Kovesdy, Danh V Nguyen, Connie M Rhee

Open access · bronzeAbstract read
In one paragraph

Article in Mayo Clinic proceedings, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Dialysis adequacy revisited: Kt/V's blind spot for phosphorus and iodine.Journal of translational internal medicine · 2025
    Article
  7. Article
  8. Hormones and Nephrons: Disentangling the Thyroid-Kidney Connection.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Amy S YouDivision of Nephrology, Hypertension, and Kidney Transplantation, University of California Irvine, Orange, CA; Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA.
Kamyar Kalantar-ZadehDivision of Nephrology, Hypertension, and Kidney Transplantation, University of California Irvine, Orange, CA; Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA.
Gregory A BrentDivision of Endocrinology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA.
Yoko NarasakiDivision of Nephrology, Hypertension, and Kidney Transplantation, University of California Irvine, Orange, CA; Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA.
Andrea DazaDivision of Nephrology, Hypertension, and Kidney Transplantation, University of California Irvine, Orange, CA; Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA.
John J SimDivision of Nephrology and Hypertension, Kaiser Permanente Southern California, Los Angeles, CA.
Csaba P KovesdyDivision of Nephrology, University of Tennessee Health Science Center, Memphis, TN; Memphis Veterans Affairs Medical Center, Memphis, TN.
Danh V NguyenTibor Rubin Veterans Affairs Medical Center, Long Beach, CA; Division of General Internal Medicine, University of California Irvine, Orange, CA.
Connie M RheeDivision of Nephrology, Hypertension, and Kidney Transplantation, University of California Irvine, Orange, CA; Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA. Electronic address: crhee1@uci.edu.
University of California, Irvine · USKaiser Permanente · USUniversity of California, Los Angeles · USUniversity of Tennessee Health Science Center · US

Funding

Multilevel Time-Dynamic Modeling of Hospitalization and Survival in Patients on DialysisR01DK092232 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KURUM, ESRA, NGUYEN, DANH V · 2011 to 2025
$4.9M
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis PatientsR01DK122767 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RHEE, CONNIE MEEYOUNG · 2019 to 2023
$3.3M
Defining Optimal Transitions of Care in Advanced Kidney Disease: Conservative Management vs. Dialysis ApproachesR01DK124138 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KALANTAR-ZADEH, KAMYAR, RHEE, CONNIE MEEYOUNG · 2020 to 2024
$2.9M
MALNUTRITION, DIET AND RACIAL DISPARITIES IN CKDK24DK091419 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI KALANTAR-ZADEH, KAMYAR · 2011 to 2020
$1.8M
Novel Saliva-based Renal Function Test PlatformR44DK116383 · NIDDK · INTELLIGENT OPTICAL SYSTEMS, INC. · PI KALANTAR-ZADEH, KAMYAR, NGUYEN, TRONG · 2018 to 2020
$1.7M
Hypothyroidism, Cardiovascular Health, and Survival in Kidney DiseaseK23DK102903 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI RHEE, CONNIE MEEYOUNG · 2014 to 2018
$955k
A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis PatientsR03DK114642 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI RHEE, CONNIE MEEYOUNG · 2017 to 2018
$155k
NIDDK NIH HHS K23 DK102903NIDDK NIH HHS K24 DK091419NIDDK NIH HHS R01 DK092232NIDDK NIH HHS R01 DK122767NIDDK NIH HHS R01 DK124138NIDDK NIH HHS R03 DK114642NIDDK NIH HHS R44 DK116383
6 · The paper itself

Abstract

objectiveTo examine the relationship between thyroid status and incident kidney dysfunction/chronic kidney disease (CKD) progression. PATIENTS AND

methodsWe examined incident thyroid status, ascertained by serum thyrotropin (TSH) levels measured from January 1, 2007, through December 31, 2018, among 4,152,830 patients from the Optum Labs Data Warehouse, containing deidentified retrospective administrative claims data from a large national health insurance plan and electronic health record data from a nationwide network of provider groups. Associations of thyroid status, categorized as hypothyroidism, euthyroidism, or hyperthyroidism (TSH levels >5.0, 0.5-5.0, and <0.5 mIU/L, respectively), with the composite end point of incident kidney dysfunction in patients without baseline kidney dysfunction and CKD progression in those with baseline CKD were examined using Cox models.

resultsPatients with hypothyroidism and hyperthyroidism had higher risk of incident kidney dysfunction/CKD progression in expanded case-mix analyses (reference: euthyroidism): adjusted hazard ratios (aHRs) (95% CIs) were 1.37 (1.34 to 1.40) and 1.42 (1.39 to 1.45), respectively. Incrementally higher TSH levels in the upper reference range and TSH ranges for subclinical, mild overt, and overt hypothyroidism (≥3.0-5.0, >5.0-10.0, >10.0-20.0, and >20.0 mIU/L, respectively) were associated with increasingly higher risk of the composite end point (reference: TSH level, 0.5 to <3.0 mIU/L): aHRs (95% CIs) were 1.10 (1.09 to 1.11), 1.37 (1.34 to 1.40), 1.70 (1.59 to 1.83), and 1.70 (1.50 to 1.93), respectively. Incrementally lower TSH levels in the subclinical (<0.5 mIU/L) and overt (<0.1 mIU/L) hyperthyroid ranges were also associated with the composite end point: aHRs (95% CIs) were 1.44 (1.41 to 1.47) and 1.48 (1.39 to 1.59), respectively.

conclusionIn a national cohort, TSH levels in the upper reference range or higher (≥3.0 mIU/L) and below the reference range (<0.5 mIU/L) were associated with incident kidney dysfunction/CKD progression.

Indexed as

HyperthyroidismHypothyroidismRenal Insufficiency, ChronicHumansKidneyRetrospective StudiesThyrotropinThyroxineThyrotropinThyroxine

Identifiers

PMID38176833
PMCPMC10795379
OpenAlexW4390509516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.